spacer
home > ebr > autumn 2017 > homing in
PUBLICATIONS
European Biopharmaceutical Review

Homing In

Since the first daVinci surgical systems began marketing in 1999 and the following acquisition of Computer Motion by Intuitive Surgical in 2003, very few innovations have been made in the field. Initial adoption of such technology was limited and most surgeons were highly sceptical about its future. However, over the span of 15 years, Intuitive Surgical transformed robotic surgery from an interesting market experiment to an established technique. Today, analysts project exponential growth in the years to come, and nobody doubts that the future is in robotics.

As initial patents expire and new technologies are developed, a rising number of modern robotic surgical systems have been, or are about to be, launched. The competition for shares will be fierce.

Perfecting Platforms

The market might seem big enough for everybody, but the reality could be more complex. For most hospitals, adopting a given robotic surgical platform is a big decision and is not easily reversible, as it involves significant costs and efforts, such as staff training. Due to the requirements for an increased number of operating rooms and storage, a costly multi-platform-adapted staff and a complex maintenance organisation, working with two different types of robotic platforms is also unlikely. However, bigger hospitals that might actually need to utilise several robotic platforms could reduce costs by taking advantage of economies of scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Andre Faure has a surgical background and decided to interrupt his early medical career to develop new surgical devices. For more than 15 years, he has led several multi-national R&D programmes in the field where he has developed robotic surgical instruments, including devices for treating atrial fibrillation and liver cancer. Andre is also the founder of Trod Medical, a company created around one of his inventions – a robotic device specifically developed for localised prostate cancer treatment.
spacer
Dr Andre Faure
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

Cambridge, UK, 22 January 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.
More info >>

White Papers

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

Phlexglobal Ltd

Looking at some of the challenges of traditional paper-based Trial Master Files (TMFs), and how they can be overcome with Phlexglobal's best in breed electronic TMF system, PhlexEview.
More info >>

 
Industry Events

11th Annual Proteins & Antibodies Congress

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our esteemed 11thAnnual Proteins & Antibodies Congress 2018, 16th – 17th April 2018, London, UK. Over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement